Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Anti-Müllerian hormone in PCOS: a review informing international guidelines|
|Citation:||Trends in Endocrinology and Metabolism, 2019; 30(7):467-478|
|Helena Teede, Marie Misso, Eliza C.Tassone, Didier Dewailly, Ernest HyNg, Ricardo Azziz ... Robert J.Norman ... et al.|
|Abstract:||Polycystic ovary syndrome (PCOS) affects 8-13% of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-Müllerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.|
polycystic ovary syndrome
|Rights:||© 2019 Published by Elsevier Ltd.|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.